Latest Phase III success puts Tonix closer to fibromyalgia nod
Tonix Pharmaceuticals Holding Corp (Nasdaq: TNXP) has announced highly statistically-significant and clinically-meaningful top-line results in a second positive Phase III trial of TNX-102 SL for the management of fibromyalgia.
The RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo, and there were significant improvements on all secondary endpoints, including patient global impression, fibromyalgia-specific symptoms and dysfunction, fatigue and sleep measures.
"We are now an important step closer to bringing a new, first-line treatment to fibromyalgia patients"These results support the US biopharma’s planned New Drug Application (NDA) filing to the US Food and Drug Administration (FDA) in the second half of 2024, adding to data from three years ago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze